179 related articles for article (PubMed ID: 23318434)
1. Dual regulation of Myc by Abl.
Sanchez-Arévalo Lobo VJ; Doni M; Verrecchia A; Sanulli S; Fagà G; Piontini A; Bianchi M; Conacci-Sorrell M; Mazzarol G; Peg V; Losa JH; Ronchi P; Ponzoni M; Eisenman RN; Doglioni C; Amati B
Oncogene; 2013 Nov; 32(45):5261-71. PubMed ID: 23318434
[TBL] [Abstract][Full Text] [Related]
2. Pin1 links the activities of c-Abl and p300 in regulating p73 function.
Mantovani F; Piazza S; Gostissa M; Strano S; Zacchi P; Mantovani R; Blandino G; Del Sal G
Mol Cell; 2004 Jun; 14(5):625-36. PubMed ID: 15175157
[TBL] [Abstract][Full Text] [Related]
3. c-Myc inhibition decreases CIP2A and reduces BCR-ABL1 tyrosine kinase activity in chronic myeloid leukemia.
Lucas CM; Harris RJ; Giannoudis A; Clark RE
Haematologica; 2015 May; 100(5):e179-82. PubMed ID: 25661443
[No Abstract] [Full Text] [Related]
4. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis.
Farrell AS; Pelz C; Wang X; Daniel CJ; Wang Z; Su Y; Janghorban M; Zhang X; Morgan C; Impey S; Sears RC
Mol Cell Biol; 2013 Aug; 33(15):2930-49. PubMed ID: 23716601
[TBL] [Abstract][Full Text] [Related]
5. Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
Williamson EA; Burgess GS; Eder P; Litz-Jackson S; Boswell HS
Leukemia; 1997 Jan; 11(1):73-85. PubMed ID: 9001421
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
7. The linchpin? Pin1 meets p73.
Urist M; Prives C
Cancer Cell; 2004 Jun; 5(6):515-7. PubMed ID: 15193253
[TBL] [Abstract][Full Text] [Related]
8. A critical step for JNK activation: isomerization by the prolyl isomerase Pin1.
Park JE; Lee JA; Park SG; Lee DH; Kim SJ; Kim HJ; Uchida C; Uchida T; Park BC; Cho S
Cell Death Differ; 2012 Jan; 19(1):153-61. PubMed ID: 21660049
[TBL] [Abstract][Full Text] [Related]
9. Jak2 is involved in c-Myc induction by Bcr-Abl.
Xie S; Lin H; Sun T; Arlinghaus RB
Oncogene; 2002 Oct; 21(47):7137-46. PubMed ID: 12370803
[TBL] [Abstract][Full Text] [Related]
10. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia.
Shinohara H; Taniguchi K; Kumazaki M; Yamada N; Ito Y; Otsuki Y; Uno B; Hayakawa F; Minami Y; Naoe T; Akao Y
Cancer Lett; 2015 Apr; 360(1):28-38. PubMed ID: 25644089
[TBL] [Abstract][Full Text] [Related]
11. Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage.
Kusio-Kobialka M; Wolanin K; Podszywalow-Bartnicka P; Sikora E; Skowronek K; McKenna SL; Ghizzoni M; Dekker FJ; Piwocka K
Apoptosis; 2012 Sep; 17(9):950-63. PubMed ID: 22696202
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines.
Xu Y; Voelter-Mahlknecht S; Mahlknecht U
Int J Mol Med; 2005 Jan; 15(1):169-72. PubMed ID: 15583844
[TBL] [Abstract][Full Text] [Related]
13. Janus kinase 2: a critical target in chronic myelogenous leukemia.
Samanta AK; Lin H; Sun T; Kantarjian H; Arlinghaus RB
Cancer Res; 2006 Jul; 66(13):6468-72. PubMed ID: 16818614
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of survivin by c-Myc in BCR/ABL-transformed cells: implications in anti-leukaemic strategy.
Fang ZH; Dong CL; Chen Z; Zhou B; Liu N; Lan HF; Liang L; Liao WB; Zhang L; Han ZC
J Cell Mol Med; 2009 Aug; 13(8B):2039-2052. PubMed ID: 19602047
[TBL] [Abstract][Full Text] [Related]
15. Pin1 is overexpressed in breast cancer and cooperates with Ras signaling in increasing the transcriptional activity of c-Jun towards cyclin D1.
Wulf GM; Ryo A; Wulf GG; Lee SW; Niu T; Petkova V; Lu KP
EMBO J; 2001 Jul; 20(13):3459-72. PubMed ID: 11432833
[TBL] [Abstract][Full Text] [Related]
16. Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis.
Wulf G; Garg P; Liou YC; Iglehart D; Lu KP
EMBO J; 2004 Aug; 23(16):3397-407. PubMed ID: 15257284
[TBL] [Abstract][Full Text] [Related]
17. Molecular biology of chronic myeloid leukemia.
Maru Y
Int J Hematol; 2001 Apr; 73(3):308-22. PubMed ID: 11345196
[TBL] [Abstract][Full Text] [Related]
18. Pin1 is required for sustained B cell proliferation upon oncogenic activation of Myc.
D'Artista L; Bisso A; Piontini A; Doni M; Verrecchia A; Kress TR; Morelli MJ; Del Sal G; Amati B; Campaner S
Oncotarget; 2016 Apr; 7(16):21786-98. PubMed ID: 26943576
[TBL] [Abstract][Full Text] [Related]
19. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
20. IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation.
Massimino M; Consoli ML; Mesuraca M; Stagno F; Tirrò E; Stella S; Pennisi MS; Romano C; Buffa P; Bond HM; Morrone G; Sciacca L; Di Raimondo F; Manzella L; Vigneri P
Carcinogenesis; 2014 May; 35(5):1132-43. PubMed ID: 24445143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
